SCHEMBL3435608

SCHEMBL3435608

Cc1cc(CO)nn1Cc1cc(Cl)ccc1OCc1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 20/20 0.61
CYP2C9 P11712 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL251373 0.93 PTGER1 (0.71) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL3433815 0.86 PTGER1 (0.64) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL18560414 0.86 PTGER1 (0.67) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL4096456 0.85 PTGER1 (0.64) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL3434489 0.85 PTGER1 (0.61) PTGER1
SCHEMBL19547231 0.85 PTGER1 (0.62) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL3433669 0.84 PTGER1 (0.62) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL255383 0.84 PTGER1 (0.56) PTGER1CYP2C9CYP1A2CYP2C19
SCHEMBL255384 0.84 PTGER1 (0.56) PTGER1
SCHEMBL4683984 0.83 PTGER1 (0.85) PTGER1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2945932-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2018-11-21 EP disclosed
EP-2588459-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-03-01 EP disclosed
EP-2588459-B1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN INC (US) 2017-03-01 EP disclosed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US disclosed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US disclosed
US-9394284-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2016-07-19 US disclosed
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2015-03-19 US disclosed
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2015-03-19 US disclosed
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. 2015-03-19 US disclosed
US-8859606-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2014-10-14 US disclosed
US-20130253028-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-09-26 US disclosed
US-20130253028-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-09-26 US disclosed
US-8492424-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-8492424-B2 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response ALLERGAN, INC. (US) 2013-07-23 US disclosed
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-05-23 US disclosed
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-05-23 US disclosed
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2013-05-23 US disclosed
US-20120165382-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-06-28 US disclosed
US-20120165382-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-06-28 US disclosed
WO-2012003414-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE ALLERGAN, INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165382-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885
US-20150080446-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885
US-20130131135-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885
US-20130253028-A1 COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE PTGER1, PTGER4, CNR1 PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.